Companies Dominating the Autism Spectrum Disorder Treatment Landscape
- Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Curemark LLC
- Yamo Pharmaceuticals, LLC
- Merck & Co Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson Services, Inc.
- Bristol-Myer Squibb
- Janssen Pharmaceuticals, Inc.
- Axial Therapeutics, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of gaming PC is estimated at USD 2.44 billion.
The autism spectrum disorder treatment market size was valued at USD 2.32 billion in 2024 and is likely to cross USD 5.13 billion by 2037, expanding at more than 6.3% CAGR during the forecast period i.e., between 2025-2037. Growing government efforts on raising funds and awareness for autism as well as increasing research and development will boost the market growth.
North America industry is estimated to account for largest revenue share of 30% by 2037, impelled by research & development in the region.
The major players in the market are Pfizer, Inc., Novartis AG, Curemark LLC, Yamo Pharmaceuticals, LLC, Merck & Co Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Bristol-Myer Squibb, Janssen Pharmaceuticals, Inc., Axial Therapeutics, Inc.
